Is Preventative Oophorectomy Safe? – OncoDaily
Is Preventative Oophorectomy Safe? / cancer, Dana-Farber’s Breast Oncology Center, Douglas E. Drachman, Erica L. Mayer, Megan E. Tesch, OncoDaily, Oncology,
Related Articles
Did headlines saying to throw out black plastic spatulas get ahead of the science? | CBC News
Headlines warning people to throw out their black plastic kitchen utensils live on, as do social media posts warning of “secret toxins” in your kitchen.…
5 Articles in Immunotherapy suggested by Wafik El-Deiry – OncoDaily
5 Articles in Immunotherapy suggested by Wafik El-Deiry / A. Ari Hakimi, Abhinav Pandey, Akshay J. Patel, Andrew Sangho Lee, Anuj Wali, Attila A. Seyhan,
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
Key Points. Epcoritamab, a CD3xCD20 bispecific antibody, plus GemOx yields deep, durable responses in second-line or later ASCT-ineligible R/R DLBCLHigher
The Real Reason People Don’t Trust in Science Has Nothing to Do with Scientists
Propaganda works, is the real upshot of a survey showing lingering post-pandemic distrust of science
Financial Toxicity in Cancer Care: Where Are We, and How Did We Get Here? Introduction to a Special Series | JCO Oncology Practice
The first academic article using the term “financial toxicity” was published in 2013, 1 which catalyzed the growth of an emerging field of research and…
Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a…
Financial Toxicity in Older Adults With Cancer and Their Caregivers | JCO Oncology Practice
With advances in cancer treatment, long-term survival rates have improved in recent decades, resulting in extended life expectancies for many patients. This progress brings substantial…
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases
Click on the article title to read more.
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
The Mayo genetic risk models offer pre-treatment and response-based prognostic tools for newly diagnosed AML treated with Ven-HMA.
Mike Lupica: Patient John Mara better be right about these Giant decisions
Here is what happened with the Giants this week when John Mara decided to keep Joe Schoen as his general manager and Brian Daboll as…
